Valeritas Holdings, Inc. (VLRX) Receives Consensus Rating of “Strong Buy” from Analysts
Shares of Valeritas Holdings, Inc. (NASDAQ:VLRX) have been assigned a consensus broker rating score of 1.00 (Strong Buy) from the two brokers that cover the stock, Zacks Investment Research reports. Two research analysts have rated the stock with a strong buy recommendation.
Brokerages have set a 12-month consensus price objective of $13.50 for the company and are expecting that the company will post ($1.69) EPS for the current quarter, according to Zacks. Zacks has also given Valeritas an industry rank of 176 out of 265 based on the ratings given to related companies.
Separately, ValuEngine upgraded shares of Valeritas from a “strong sell” rating to a “sell” rating in a report on Friday, December 1st.
Shares of Valeritas (NASDAQ:VLRX) traded down $0.14 during mid-day trading on Wednesday, hitting $4.19. 8,021 shares of the stock traded hands, compared to its average volume of 30,643. The company has a current ratio of 3.88, a quick ratio of 3.20 and a debt-to-equity ratio of 3.54. Valeritas has a 52-week low of $2.00 and a 52-week high of $40.00.
TRADEMARK VIOLATION WARNING: This article was first reported by American Banking News and is the property of of American Banking News. If you are viewing this article on another site, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/12/06/valeritas-holdings-inc-vlrx-receives-consensus-rating-of-strong-buy-from-analysts.html.
Valeritas Company Profile
Valeritas, Inc is a United States-based company, which is engaged in developing and commercializing treatment solutions that contribute to clinical outcomes for patients. The Company’s portfolio includes V-Go disposable insulin delivery device, which is distributed through retail pharmacy. Its V-Go delivers insulin at a continuous preset basal rate and bolus dosing for adults with Type 2 diabetes requiring insulin.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Valeritas Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeritas Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.